Important Deadline Approaches for REGENXBIO Investors in Class Action Lawsuit

Faruqi & Faruqi, LLP, a renowned national securities law firm, has highlighted a crucial deadline for investors in REGENXBIO Inc., reminding them of the opportunity to participate in a federal class action. The deadline to apply as a lead plaintiff is set for April 14, 2026. This class action alleges that REGENXBIO and its executives made misleading statements regarding their clinical trials, particularly concerning the RGX-111 gene therapy, which has reportedly encountered regulatory challenges.

The firm has been investigating these potential claims following an announcement by REGENXBIO on January 28, 2026, when it disclosed that the FDA had placed a clinical hold on RGX-111 after a neoplasm case was identified in a trial participant. The news led to a sharp decline in REGENXBIO’s stock price, underscoring the impact of the alleged misstatements on shareholders. Investors who acquired securities of REGENXBIO between February 9, 2022, and January 27, 2026, are invited to contact Faruqi & Faruqi for further discussion about their legal options.

The class action underscores the significant risks inherent in investing in clinical trial-based companies. With the FDA’s halt on RGX-111 and another gene therapy, RGX-121, related to similar safety concerns, investors may now face increased scrutiny regarding the viability of their investments. Reports indicate that following the announcement, the stock price dropped by 17.9%, prompting calls for accountability from company executives and the board.

In the realm of securities litigation, a lead plaintiff represents the largest financial interest in the case and oversees the proceedings on behalf of all class members. Potential participants in the class action are encouraged to consider their options seriously, as involvement or lack thereof will not affect their recovery rights. This fact highlights the importance of engaging competent legal counsel to navigate the complexities associated with such proceedings.

Faruqi & Faruqi, which celebrated over 25 years of successful representation for investors, is committed to bringing justice for shareholders affected by misleading corporate conduct. The firm assures potential clients that communication will be handled with the utmost confidentiality and emphasizes the importance of community insight for such cases. Anyone with information relevant to REGENXBIO's operations, including whistleblowers and former employees, is urged to come forward to aid the ongoing investigation.

For more information about the REGENXBIO class action, interested parties can visit Faruqi & Faruqi’s dedicated page or reach out directly to partner Josh Wilson, who is available for inquiries. Engaging in this lawsuit may not only serve individual interests but also contribute to ensuring accountability in corporate governance practices in the biotechnology sector. With significant implications for investor rights and the integrity of clinical trials, this case could impact how biotechnology firms communicate trial results and regulatory actions in the future.

Understanding these issues is crucial for investors who wish to safeguard their investments and participate actively in holding corporations accountable for their actions. Firms like Faruqi & Faruqi are vital in representing investor interests and ensuring that there is a platform for those impacted by corporate misconduct to voice their concerns and seek restitution.